medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2007; 8 (1)


Esclerosis múltiple

Porras-Betancourt M, Núñez-Orozco L, Plascencia-Álvarez NI, Quiñones-Aguilar S, Sauri-Suárez S

Idioma: Español
Referencias bibliográficas: 68
Paginas: 57-66
Archivo PDF: 495.88 Kb.


RESUMEN

La esclerosis múltiple (EM) es considerada una enfermedad autoinmune, crónica, inflamatoria, desmielinizante del sistema nervioso central (SNC), se presenta en individuos genéticamente susceptibles e involucra a factores inmunológicos como anticuerpos, complemento y mediadores de la respuesta inmune innata. Se le considera dentro de las enfermedades desmielinizantes inflamatorias idiopáticas y constituye una de las causas más frecuentes de discapacidad neurológica en adultos jóvenes. El 50% de los pacientes es incapaz de caminar a los 15 años después del inicio. Se sabe poco sobre el gen involucrado, aunque se sugiere un factor genético.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Blevins G, Martin R. Future immunotherapies in multiple sclerosis. Semin Neurol 2003; 23: 147-58.

  2. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005; 23: 17-38.

  3. Polman CH, Uitdehaag BM. Regular review: Drug treatment of multiple sclerosis. BMJ 2000; 321: 490-4.

  4. Rivera Olmos VM. Introducción. En: Núñez Orozco L. El manejo integral de la Esclerosis Múltiple. 1ª edición. México: Editorial Prado; 2003, XIV-XVIII.

  5. McDonald WI. The history of multiple sclerosis. In: Cook SD. Handbook of Multiple Sclerosis. 3rd. Ed. New York: Ed. Marcel Dekker, Inc.; 2001, p. 1-14.

  6. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.

  7. Lassman H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Springer; 1983.

  8. Prineas JW, Kwon EE, Cho ES, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. In: Scheinberg L, Raine CS, eds. Multiple sclerosis: Experimental and clinical aspects, vol. 436. Annals of New York Academy of Sciences, 1984.

  9. Ghatak NR, Leshner RT, Price AC, Felton WL. Remyelination in human central nervous system. J Neuropathol Exp Neurol 1989; 48: 507-18.

  10. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: Pathology and recurrent lesions. Brain 1993; 116: 681-93.

  11. Raine CS. The dale E McFarlin memorial lecture: The immunology of multiple sclerosis lesion. Ann Neurol 1994; 36: S61-S72.

  12. McDonald WI, Sears TA. The effects of experimental demyelination on conduction in central nervous system. Brain 1970; 583-98.

  13. Moll C, Mourre C, Lazdunsky M, Ulrich J. Increase in sodium channels in demyelinated lesions in multiple sclerosis. Brain Res 1991; 544: 59-70.

  14. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996; 347: 1728-30.

  15. Fleming JO. Diagnosis and management of multiple sclerosis. 1st edition. Ed. Professional Communications Inc. 2002.

  16. Rice GP. The genetic epidemiology of multiple sclerosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 28-37.

  17. Dyment DA, Willer CJ, Scott B, et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics 2001; 3: 145-51.

  18. Cook SD. Evidence for a viral etiology in multiple sclerosis. In: Cook SD. Handbook of Multiple Sclerosis. 3rd. Ed. New York: Ed. Marcel Dekker, Inc.; 2001, p. 115-38.

  19. García-Pedroza F. Neuroepidemiología de la esclerosis múltiple. En: Núñez Orozco L. El manejo integral de la esclerosis múltiple. 1ª. edición. México: Editorial Prado; 2003, p. 7-18.

  20. Alter M, Olivares L. Multiple sclerosis in Mexico: An epidemiologic study. Arch Neurol 1970; 23: 451.

  21. Corona T, Rodríguez JL, Otero E, Stoop L. Multiple sclerosis in Mexico. Epidemiology and clinical funding at the National Institute of Neurology and Neurosurgery (Mexico). Neurología (Español) 1996; 11: 170-3.

  22. González O, Sotelo J. Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.

  23. Velázquez Quintana M, Macías Islas MA, Rivera Olmos V, Lozano Zárate J. Grupo Mexicano de Estudio de la Esclerosis Múltiple. Esclerosis múltiple en México: un estudio multicéntrico. Rev Neurol 2003; 36(11): 1019-22.

  24. Mexican Group for the study of Multiple Sclerosis. Multiple sclerosis: validation of a questionnaire to characterize the disease patterns in Mexican population. Multiple Sclerosis 1999; 5: 75.

  25. Schumacher GA, Beebe G, Kibler RF, Kurlant LT, Kurtzke JF, McDowell F. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Med 1965; 122: 552-66.

  26. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.

  27. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.

  28. Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry 1990; 53: 906-11.

  29. Kurtzke JF, Hyllested K, Heltberg A. Multiple sclerosis in the Faeroe Islands: transmission across four epidemics. Acta Neurol Scand 1995; 91: 321-5.

  30. Noseworthy JH, Lucchinetti IC, Rodriguez M, Weinshenker BG. Medical Progress: Multiple Sclerosis. N Eng J Med 2000; 343(13): 938-52.

  31. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.

  32. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.

  33. Lucchinetti C, Brueck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14: 259-69.

  34. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000; 343: 108-17.

  35. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells and monocytes produce brainderived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role for inflammation? J Exp Med 1999; 189: 865-70.

  36. Miller JR. Multiple sclerosis. In: Rowland LP. Merritt’s Neurology. 10th edition. Lippincott Williams & Wilkins 2000; 773-92.

  37. Coyle PK. Multiple sclerosis clinical variants and differential diagnosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 38-73.

  38. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.

  39. Miller AE, Coyle PK. Clinical features in multiple sclerosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 38-73.

  40. Paty DW, Oger JJ, Kastrukoff LF. MRI in the diagnosis of multiple sclerosis: a perspective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988; 38: 180-5.

  41. Fasekas F, Offenbacher H, Fuchs S. Criteria of a increased specificity of MRI interpretation in elderly subjets with suspected multiple sclerosis. Neurology 1988; 38: 1822-55.

  42. Barkhof F, Filippi M, Miller DH. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.

  43. Kurtzke FJ. Epidemiology of multiple sclerosis. Baker’s Clinical Neurology on CD-ROM. Ed. Lippincott Williams & Wilkins 2000.

  44. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

  45. McDonald WI. The History of Multiple Sclerosis. In: Cook SD. Handbook of Multiple Sclerosis. Ed. Marcel Dekker Inc. 3rd. edition, New York 2001; 1-14.

  46. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5.

  47. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrona combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-18.

  48. Jacobs LD, Cookfair DL, Rudick RA, et al. for the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta 1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.

  49. The IFNB multiple sclerosis study group. Interferon beta 1b is effective in relapsing-remmiting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.

  50. Johnson KP, Brooks BR, Cohen JA, et al. for the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsingremmiting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.

  51. Lublin FD. Treatment for multiple sclerosis. In: Continuum. Multiple Sclerosis. Lippincott Williams & Wilkins 2004; 10(6): 120-41.

  52. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58(Suppl. 4): S3-S9.

  53. Dhib-Jalbut S. Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3: 397-401.

  54. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-9.

  55. Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon beta in multiple sclerosis include the up regulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-57.

  56. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48: 1446-8.

  57. Goodin DS, Frohman EM, Garmany Jr. GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169-78.

  58. Kappos L. Interferons in multiple sclerosis. Neurol Clin 2005; 23: 189-214.

  59. The PRISMS study. Randomized double-blind placebocontrolled study of interferon b-1b in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.

  60. The PRISMS Study Group, University of British Columbia MS/ MRI Analysis Group. PRISMS-4: long-term efficacy of interferonbeta- 1a in relapsing MS. Neurology 2001; 56: 1628-36.

  61. Clanet M, Raduc EW, Kappos L, et al. Arandomized, double-blind, dose-comparison study of weekly interferon beta-1a (Avonex) in relapsing-remitting MS. Neurology 2002; 59: 1507-17.

  62. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63(Suppl. 6): S8-S14.

  63. Boneschi FM, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003; 9: 349-55.

  64. Aguilar RF. Interferones en Neurología. Rev Invest Clin 2000; 52(6): 665-79.

  65. Gonorazky SE. Tratamiento de esclerosis múltiple con interferón beta y acetato de glatiramer: Evaluación del costo relacionado a la eficacia en Argentina. Rev Neurol Arg 2002; 27: 24-9.

  66. Cabrera-Gómez JA, López-Saura P. Interferón alfa en el tratamiento de la esclerosis múltiple. Actualización y experiencia en Cuba. Rev Neurol 1999; 28: 849-58.

  67. León C, Violante A, Arriada N, Santana HR, Corona T. El interferón beta 1-a en el tratamiento de la esclerosis múltiple con curso remitente recurrente. Primera descripción en una población mexicana. Rev Neurol 2000; 31(11): 1019-22.

  68. Rangel Guerra R, Muñoz Landeros C. Experiencia Clínica con Interferón beta 1-b en 30 pacientes con diagnóstico de esclerosis múltiple en el noreste de México. Medicina Universitaria 2004; 6(24): 182-7.




2020     |     www.medigraphic.com